Genmab — August 2015
-
Did Gilead Sciences Just Give Wall Street a Huge Head Fake? | The Motley Fool
Gilead Sciences is believed to be seriously interested in acquiring a hematology/oncology company in the near future. But management threw some cold water on this notion in its second-quarter conference call. Are these comments sincere, or did the biotech just throw the Street a curve ball to hide its real intentions?
The Motley Fool (www.fool.com)
-
Er du i dialyse ? https://en.wikipedia.org/wiki/Alirocumab
-
-
-
På den alternative kanal henvises til dette klip http://play.borsen.dk/share/55c4c44dac79c95260fa06f0
-
-
-
-
Det handler om en amerikansk forsøg i forbindelse rygestop.
-
med
-
Amerikanere betales for at stoppe med rygning.
-
Det virker åbenbart.
-
Sydbank ude med kommentarer omkring Genmab og kvartalsregnskabet: http://www.proinvestor.com/analyser
-
Jeg kan godt forstå at Sydbank nedjusterer arzerra - specielt når de tror, at det stadig er GSK, der står for salget....
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind